Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against AlloVir, Inc. due to allegations of violations of federal securities laws related to misleading statements about the posoleucel Phase 3 studies [1][2]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $25,000 in AlloVir stock or options between March 22, 2022, and December 21, 2023, to contact them for legal options [1]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2]. Allegations Against AlloVir - The complaint alleges that AlloVir and its executives made false and misleading statements regarding the posoleucel Phase 3 studies, including: - The studies were unlikely to meet their primary endpoints [2]. - The likelihood of discontinuation of the posoleucel Phase 3 studies [2]. - Overstating the efficacy and commercial prospects of posoleucel [2]. - Public statements made by the company were materially false and misleading [2]. Stock Price Impact - Following the announcement on December 22, 2023, that AlloVir would discontinue the posoleucel Phase 3 studies due to efficacy concerns, the stock price fell by $1.57 per share, or 67.38%, closing at $0.76 per share [3]. Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [3]. - Any member of the class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [3].

Group 1 - AlloVir, Inc. (ALVR) has shown a year-to-date return of approximately 4.4%, outperforming the Medical sector average return of about -0.9% [2][3] - The Zacks Consensus Estimate for ALVR's full-year earnings has increased by 57.9% in the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [2] - AlloVir, Inc. currently holds a Zacks Rank of 2 (Buy), suggesting it is positioned to outperform the broader market in the near term [1][2] Group 2 - AlloVir, Inc. is part of the Medical - Drugs industry, which consists of 192 individual stocks and is currently ranked 94 in the Zacks Industry Rank [3] - The Medical - Drugs industry has experienced a year-to-date loss of about -0.9%, indicating that ALVR is performing better than its industry peers [3] - In comparison, Arcutis Biotherapeutics, Inc. (ARQT), another stock in the Medical sector, has achieved a year-to-date return of 64.1% and also holds a Zacks Rank of 2 (Buy) [2][3]

A downtrend has been apparent in AlloVir, Inc. (ALVR) lately with too much selling pressure. The stock has declined 72.4% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________to __________________ Commission File Number: 001-39409 ALLOVIR, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________to __________________ Commission File Number: 001-39409 ALLOVIR, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________to __________________ Commission File Number: 001-39409 ALLOVIR, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State ...

Allogeneic, Off-the-Shelf, Virus-Specific T Cell Therapies in Late-Stage Development February 2023 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39409 ALLOVIR, INC. (Exact name of Registrant as specified in its Charter) Delaware 83-1971007 (State or other jurisdiction of incorp ...

Allogeneic, Off-the-Shelf, Virus-Specific T Cell Therapies in Late-Stage Development January 2023 ...